Sumitomo Pharma Co

Sumitomo Pharma Co Gross Margin

The Gross Margin of Sumitomo Pharma Co (4506.T) as of Nov 20, 2026 is 56.67 %. In the previous year, Gross Margin was 56.51 % — a change of 0.29% (higher).

Gross Margin

56.67 %

YoY

0.29%

Last updated:

Gross Margin of Sumitomo Pharma Co is 2026 56.67 % . Gross Margin of Sumitomo Pharma Co was 2025 56.51 % . It decreases by 0.29% higher compared to the previous year.

For Sumitomo Pharma Co, the gross margin of 56.7% is down versus 66.3% a few years ago.

The Sumitomo Pharma Co Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2019
73.56 JPY
Jan 1, 2020
70.80 JPY
Jan 1, 2021
70.08 JPY
Jan 1, 2022
66.28 JPY
Jan 1, 2023
61.73 JPY
Jan 1, 2024
49.94 JPY
Jan 1, 2025
56.51 JPY
Jan 1, 2026
56.67 JPY
The Sumitomo Pharma Co Gross Margin history
YEARGross MarginYoY
56.67 %+0.29%
56.51 %+13.16%
49.94 %-19.11%
61.73 %-6.86%
66.28 %-5.43%
70.08 %-1.01%
70.80 %-3.75%
73.56 %-1.30%
74.53 %-1.15%
75.40 %+3.76%
72.67 %+1.84%
71.36 %+2.76%
69.44 %+10,832.81%
0.64 %-0.64%
0.64 %+1.79%
0.63 %+0.67%
0.62 %+2.78%
0.61 %-2.65%
0.62 %+0.62%
0.62 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sumitomo Pharma Co Stock analysis

What does Sumitomo Pharma Co do? Sumitomo Dainippon Pharma Co Ltd is a biopharmaceutical company headquartered in Osaka, Japan. It was originally founded as Dainippon Pharmaceutical Co. Ltd in 1885 and later merged with Sumitomo Pharmaceuticals in 2005 to form the new Sumitomo Dainippon Pharma. The company operates in various areas, such as psychiatric and neurological medicine, oncology, dermatology, and infectious diseases. The products include both prescription and over-the-counter medications. In psychiatric and neurological medicine, Sumitomo Dainippon Pharma offers drugs that can be used to treat depression, anxiety disorders, schizophrenia, and bipolar disorders. One of the most well-known medications in this category is the antipsychotic Latuda, which is used for schizophrenia and bipolar disorder. In oncology, Sumitomo Dainippon Pharma has developed medications that can be used in the treatment of cancers such as lung, liver, pancreatic, colorectal, and blood cancer. The company is also involved in developing treatments for rare forms of cancer and immune-mediated diseases. In dermatology, Sumitomo Dainippon Pharma has developed medications for the treatment of skin and nail infections, psoriasis, and atopic dermatitis. The company is also working on innovative treatment approaches for skin cancer and other types of skin diseases. Sumitomo Dainippon Pharma is also involved in the development of treatments for infectious diseases, including medications for HIV and hepatitis C. The business model of Sumitomo Dainippon Pharma is based on the development of new drugs and the marketing of prescription and over-the-counter medications on a global level. The company focuses on researching and developing drugs that can address significant medical needs and that differentiate themselves from other medications on the market. The products are registered and marketed in various countries, especially in the US and Japan. Sumitomo Dainippon Pharma invests significantly in research and development. The company has R&D sites in Japan, the US, UK, and Ireland. It also collaborates with other companies to leverage innovative technologies and accelerate the development of new medications. Overall, Sumitomo Dainippon Pharma has a long history in the pharmaceutical industry and is committed to creating a wide range of medications and therapies for various diseases and conditions. The company is dedicated to improving the lives of patients and contributing to the well-being of society as a whole. Sumitomo Pharma Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sumitomo Pharma Co stock

Gross Margin of Sumitomo Pharma Co is 56.67 % in 2026.

Gross Margin of Sumitomo Pharma Co changed from 56.51 % to 56.67 %, representing a 0.29% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Sumitomo Pharma Co since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Sumitomo Pharma Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Sumitomo Pharma Co

All Key Metrics — Sumitomo Pharma Co